Unternehmensübersicht
ProQR Therapeutics N.V. operates as a clinical-stage biotechnology enterprise dedicated to the discovery and development of novel therapeutic medicines, with a specific strategic focus on an RNA editing platform known as Axiomer technology designed to address genetic disorders characterized by significant unmet medical needs. The company functions within the Healthcare sector and specifically the Biotechnology industry, positioning itself to capitalize on advancements in genetic medicine and potential breakthroughs in treating hereditary conditions. According to the latest available data, ProQR holds a market capitalization of $192.81M and generates annual revenue of $16.35M, supported by an operational workforce consisting of 186 employees. These valuation and revenue figures indicate that the company operates as a small-cap entity within a capital-intensive industry, where current financial resources are predominantly allocated toward research, development, and clinical trials rather than mature commercial operations, reflecting the typical lifecycle stage of a clinical-stage biotechnology firm.
Finanzielle Gesundheit
The company reported a trailing twelve-month revenue of $16.35M, while simultaneously posting a net income loss of $-42,184,000 and an EBITDA figure of $-42,544,000, a disparity that reveals a cost structure heavily weighted toward high fixed costs associated with clinical research and development activities that currently outpace revenue generation. This financial dynamic results in a free cash flow of $-32,042,376, indicating that the company is burning cash to fuel its pipeline, which limits immediate financial flexibility but is a standard operational requirement for clinical-stage entities aiming to bring therapies to market. Margin analysis shows a gross margin of 100.0%, suggesting high pricing power or negligible cost of goods sold in the early development phase, contrasted sharply by an operating margin of -192.9% and a profit margin of -258.1%, which highlights substantial operating expenses relative to revenue that are typical for companies in the pre-revenue or late clinical stages. The balance sheet displays $92.41M in cash against $15.96M in debt, resulting in a debt-to-equity ratio of 32.33, which suggests a leveraged position where equity is significantly lower than the debt load, yet the substantial cash reserve provides a buffer against short-term obligations. Liquidity is supported by a current ratio of 3.09, indicating that the company holds sufficient current assets to cover its current liabilities more than three times over, thereby mitigating immediate solvency risks despite the negative earnings. Return on Equity stands at -61.2% and Return on Assets at -19.3%, metrics that reveal management is currently deploying capital to generate value for future products rather than producing immediate profits, a characteristic feature of the biotechnology sector where losses are expected until product approval and commercialization occur.
Bewertungsanalyse
Valuation metrics for ProQR show a trailing P/E ratio that is N/A due to negative earnings, while the forward P/E is listed as -3.89, a figure that implies the market is pricing in future earnings expectations that are currently speculative and not yet realized based on historical performance. The price-to-book ratio is 3.38, indicating that the market values the company at a significant premium over its net asset value, likely reflecting the intangible value of its intellectual property, proprietary RNA editing platform, and potential pipeline assets that are not fully captured on the balance sheet. Alternative valuation measures such as a price-to-sales ratio of 11.79 and an EV/EBITDA of -2.73 suggest that investors are assessing the firm primarily on its revenue generation capability and pipeline potential rather than traditional profitability multiples, which are often negative for clinical-stage firms. The stock has traded within a 52-week range bounded by a high of $3.10 and a low of $1.07, placing the current valuation context within this historical volatility band where the specific trading price fluctuates based on clinical trial data and market sentiment regarding genetic therapies. The company exhibits a beta of 0.09, which indicates that its stock price volatility is significantly lower than the broader market, suggesting a low correlation with general market movements and potentially acting as a defensive or idiosyncratic position driven by specific company milestones rather than macroeconomic trends.
Growth & Income
ProQR Therapeutics reported a year-over-year revenue growth of 6.1%, while earnings growth is listed as N/A due to the company's ongoing losses, implying that the top-line expansion is currently the primary driver of progress rather than profitability improvements. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, meaning the entire financial focus is directed toward reinvesting earnings and cash reserves into research and development to advance its lead product candidate, AX-081. The absence of a dividend payout ratio indicates that the company prioritizes capital allocation toward clinical trials and platform development over income generation for investors, a strategy consistent with the long-term horizon required for biotechnology asset development. Overall, the growth and income profile of ProQR is defined by steady top-line expansion supported by a substantial cash balance, while income returns remain nonexistent in the short term until the company transitions from clinical-stage research to commercial revenue generation.